Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5,081.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,638 shares of the pharmaceutical company’s stock after purchasing an additional 9,452 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Vertex Pharmaceuticals were worth $3,775,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Kovack Advisors Inc. grew its holdings in Vertex Pharmaceuticals by 1.9% in the second quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in shares of Vertex Pharmaceuticals by 8.4% in the second quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company’s stock worth $144,000 after acquiring an additional 25 shares in the last quarter. Signature Wealth Management Group grew its position in shares of Vertex Pharmaceuticals by 0.6% during the second quarter. Signature Wealth Management Group now owns 4,244 shares of the pharmaceutical company’s stock worth $1,889,000 after buying an additional 26 shares in the last quarter. Hohimer Wealth Management LLC raised its stake in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. Hohimer Wealth Management LLC now owns 2,123 shares of the pharmaceutical company’s stock valued at $945,000 after purchasing an additional 26 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC lifted its holdings in Vertex Pharmaceuticals by 1.8% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 1,442 shares of the pharmaceutical company’s stock worth $565,000 after buying an additional 26 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on VRTX shares. Wells Fargo & Company increased their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Leerink Partners lifted their target price on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, December 29th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 4th. Scotiabank boosted their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $570.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday. Twenty-two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $537.05.

Vertex Pharmaceuticals Stock Up 5.7%

Shares of NASDAQ VRTX opened at $491.47 on Monday. The firm’s 50-day simple moving average is $459.98 and its 200 day simple moving average is $427.18. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68. The company has a market cap of $124.70 billion, a price-to-earnings ratio of 32.06 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.98 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 63,781 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the transaction, the chairman directly owned 24,026 shares in the company, valued at $10,792,479.20. This trade represents a 72.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark E. Bunnage sold 2,021 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the transaction, the executive vice president owned 12,914 shares in the company, valued at $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 99,352 shares of company stock valued at $45,037,314 in the last three months. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.